Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 IV E6011 in Japanese Subjects With Crohn's Disease
jRCT2080222492Phase 2Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of quetmolimab in Crohn's disease (4 arms), sponsored by EA Pharma Co., Ltd. Primary endpoint: Safety and tolerability of E6011. Started May 2014; status: completed.
02
Drugs
quetmolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080222492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222492.